Cargando…

Association between ischaemic bowel syndromes and androgen deprivation therapy in patients with prostate cancer: a retrospective cohort study

OBJECTIVE: This study investigated the risk of ischaemic bowel syndrome (IBS) in androgen deprivation therapy (ADT) users to explore the long-term outcomes of patients with prostate cancer (PC) receiving ADT treatment. METHODS: We performed a population-based retrospective cohort study. All the clin...

Descripción completa

Detalles Bibliográficos
Autores principales: Chiang, I-Ni, Huang, Chao-Yuan, Pu, Yeong-Shiau, Chang, Chao-Hsiang, Muo, Chih-Hsin, Chung, Chi-Jung, Wang, Ruey-Yun, Young, Tai-Horng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5337716/
https://www.ncbi.nlm.nih.gov/pubmed/28246133
http://dx.doi.org/10.1136/bmjopen-2016-012950
_version_ 1782512423243087872
author Chiang, I-Ni
Huang, Chao-Yuan
Pu, Yeong-Shiau
Chang, Chao-Hsiang
Muo, Chih-Hsin
Chung, Chi-Jung
Wang, Ruey-Yun
Young, Tai-Horng
author_facet Chiang, I-Ni
Huang, Chao-Yuan
Pu, Yeong-Shiau
Chang, Chao-Hsiang
Muo, Chih-Hsin
Chung, Chi-Jung
Wang, Ruey-Yun
Young, Tai-Horng
author_sort Chiang, I-Ni
collection PubMed
description OBJECTIVE: This study investigated the risk of ischaemic bowel syndrome (IBS) in androgen deprivation therapy (ADT) users to explore the long-term outcomes of patients with prostate cancer (PC) receiving ADT treatment. METHODS: We performed a population-based retrospective cohort study. All the clinical information of the study participants were acquired from the Longitudinal Health Insurance Database for Catastrophic Illness Patients in Taiwan. We extracted data for all the patients newly diagnosed with prostate malignancy (ICD-9-CM 185 or C61 in ICD-10-CM) from 2000 to 2008. The patients were then divided into two groups: 7160 male ADT cohort receiving ADT and 7160 male non-ADT comparison group frequency matched by age and index year of ADT treatment of the ADT group. Cox proportional hazard regression was used to estimate the adjusted HR and 95% CIs of the IBS risk. RESULTS: No significant difference was noted in the overall incidence rate for IBS between the ADT and non-ADT cohorts (0.86 and 0.89 per 1000 person–year, respectively, p=0.89). Even after adjusting for potential risk factors, a 1.06-fold risk of IBS (95% CI 0.62 to 1.82, p=0.82) was observed in the ADT cohort relative to the non-ADT cohorts. Moreover, we stratified the ADT cohort by time point of ADT treatment after PC diagnosis. Different IBS incidence rates were observed among the early ADT, late-ADT and non-ADT users at 0.77, 1.23 and 0.89 per 1000 person-years, respectively; nonetheless, the difference was not statistically significant. Moreover, no difference was found between the ADT treatment types and IBS risk, including sole orchiectomy, sole luteinising-hormone-releasing hormone and both. CONCLUSIONS: Results showed that ADT treatment in patients with PC is not an independent factor for IBS incidence. Large sample sizes for patients with IBS with patients with PC who had received ADT treatment are needed for further study.
format Online
Article
Text
id pubmed-5337716
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-53377162017-03-07 Association between ischaemic bowel syndromes and androgen deprivation therapy in patients with prostate cancer: a retrospective cohort study Chiang, I-Ni Huang, Chao-Yuan Pu, Yeong-Shiau Chang, Chao-Hsiang Muo, Chih-Hsin Chung, Chi-Jung Wang, Ruey-Yun Young, Tai-Horng BMJ Open Urology OBJECTIVE: This study investigated the risk of ischaemic bowel syndrome (IBS) in androgen deprivation therapy (ADT) users to explore the long-term outcomes of patients with prostate cancer (PC) receiving ADT treatment. METHODS: We performed a population-based retrospective cohort study. All the clinical information of the study participants were acquired from the Longitudinal Health Insurance Database for Catastrophic Illness Patients in Taiwan. We extracted data for all the patients newly diagnosed with prostate malignancy (ICD-9-CM 185 or C61 in ICD-10-CM) from 2000 to 2008. The patients were then divided into two groups: 7160 male ADT cohort receiving ADT and 7160 male non-ADT comparison group frequency matched by age and index year of ADT treatment of the ADT group. Cox proportional hazard regression was used to estimate the adjusted HR and 95% CIs of the IBS risk. RESULTS: No significant difference was noted in the overall incidence rate for IBS between the ADT and non-ADT cohorts (0.86 and 0.89 per 1000 person–year, respectively, p=0.89). Even after adjusting for potential risk factors, a 1.06-fold risk of IBS (95% CI 0.62 to 1.82, p=0.82) was observed in the ADT cohort relative to the non-ADT cohorts. Moreover, we stratified the ADT cohort by time point of ADT treatment after PC diagnosis. Different IBS incidence rates were observed among the early ADT, late-ADT and non-ADT users at 0.77, 1.23 and 0.89 per 1000 person-years, respectively; nonetheless, the difference was not statistically significant. Moreover, no difference was found between the ADT treatment types and IBS risk, including sole orchiectomy, sole luteinising-hormone-releasing hormone and both. CONCLUSIONS: Results showed that ADT treatment in patients with PC is not an independent factor for IBS incidence. Large sample sizes for patients with IBS with patients with PC who had received ADT treatment are needed for further study. BMJ Publishing Group 2017-02-28 /pmc/articles/PMC5337716/ /pubmed/28246133 http://dx.doi.org/10.1136/bmjopen-2016-012950 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Urology
Chiang, I-Ni
Huang, Chao-Yuan
Pu, Yeong-Shiau
Chang, Chao-Hsiang
Muo, Chih-Hsin
Chung, Chi-Jung
Wang, Ruey-Yun
Young, Tai-Horng
Association between ischaemic bowel syndromes and androgen deprivation therapy in patients with prostate cancer: a retrospective cohort study
title Association between ischaemic bowel syndromes and androgen deprivation therapy in patients with prostate cancer: a retrospective cohort study
title_full Association between ischaemic bowel syndromes and androgen deprivation therapy in patients with prostate cancer: a retrospective cohort study
title_fullStr Association between ischaemic bowel syndromes and androgen deprivation therapy in patients with prostate cancer: a retrospective cohort study
title_full_unstemmed Association between ischaemic bowel syndromes and androgen deprivation therapy in patients with prostate cancer: a retrospective cohort study
title_short Association between ischaemic bowel syndromes and androgen deprivation therapy in patients with prostate cancer: a retrospective cohort study
title_sort association between ischaemic bowel syndromes and androgen deprivation therapy in patients with prostate cancer: a retrospective cohort study
topic Urology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5337716/
https://www.ncbi.nlm.nih.gov/pubmed/28246133
http://dx.doi.org/10.1136/bmjopen-2016-012950
work_keys_str_mv AT chiangini associationbetweenischaemicbowelsyndromesandandrogendeprivationtherapyinpatientswithprostatecanceraretrospectivecohortstudy
AT huangchaoyuan associationbetweenischaemicbowelsyndromesandandrogendeprivationtherapyinpatientswithprostatecanceraretrospectivecohortstudy
AT puyeongshiau associationbetweenischaemicbowelsyndromesandandrogendeprivationtherapyinpatientswithprostatecanceraretrospectivecohortstudy
AT changchaohsiang associationbetweenischaemicbowelsyndromesandandrogendeprivationtherapyinpatientswithprostatecanceraretrospectivecohortstudy
AT muochihhsin associationbetweenischaemicbowelsyndromesandandrogendeprivationtherapyinpatientswithprostatecanceraretrospectivecohortstudy
AT chungchijung associationbetweenischaemicbowelsyndromesandandrogendeprivationtherapyinpatientswithprostatecanceraretrospectivecohortstudy
AT wangrueyyun associationbetweenischaemicbowelsyndromesandandrogendeprivationtherapyinpatientswithprostatecanceraretrospectivecohortstudy
AT youngtaihorng associationbetweenischaemicbowelsyndromesandandrogendeprivationtherapyinpatientswithprostatecanceraretrospectivecohortstudy